Drug intelligence / Profile preview

csl760

Development stage: Discontinued
Lead developer: CSL Behring
Modality: Recombinant Proteins and Enzymes, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CSL760 is a human hyperimmune product consisting of the purified gamma immunoglobulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2, the virus responsible for COVID-19. It was developed as an intravenous anti-SARS-CoV-2 hyperimmune globulin intended for passive immunotherapy in COVID-19 patients. The drug was being developed by CSL Behring, a subsidiary of CSL, and reached Phase 1 clinical trials before its development was discontinued. Its mechanism of action involves providing exogenous neutralizing antibodies to modulate immune response against SARS-CoV-2 infection[1][2][7].

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on csl760.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on csl760.

Explore the full profile